- Arcadia Biosciences Inc RKDA reported fourth-quarter revenue declined 70% year-over-year to $2.17 million, missing the consensus of $3.33 million.
- Net loss was $(9.3) million of $(0.42) per share, compared to the $8.9 million of income recognized in 4Q20, missing the consensus of $(0.30).
- RKDA reported a loss from operations of $(13.04) million for the quarter, compared to an income of $7.46 million a year ago.
- Net cash used in operating activities for FY21 totaled $25.87 million, compared to $30.22 million in FY20.
- Arcadia Biosciences held cash and cash equivalents of $28.68 million as of December 31, 2021.
- RKDA shares have gained about 60.2% year-to-date
- Price Action: RKDA shares are trading lower by 30.20% at $1.32 during the post-market session on Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
